KLRA · Kailera Therapeutics Inc. Common Stock
View on chartInsiders & Stakes
| BAIN CAPITAL INVESTORS LLC Director | ▲ Buy | Open Market | 26,255,581 Shares held | 4/20/2026 | View profile |
| Andrew T. Kaplan | ▲ Buy | Open Market | 26,255,581 Shares held | 4/20/2026 | View profile |
| Bain Capital Life Sciences Investors, LLC 10% Owner | ▲ Buy | Open Market | 22,583,268 Shares held | 4/20/2026 | View profile |
| Adam Koppel | ▲ Buy | Open Market | 22,583,268 Shares held | 4/20/2026 | View profile |
| RTW INVESTMENTS, LP 10% Owner | ▲ Buy | Open Market | 10,776,820 Shares held | 4/20/2026 | View profile |
| Jiangsu Hengrui Pharmaceuticals Co., Ltd. 10% Owner | ▼ Sell | Other | 2,034,133 Shares held | 4/20/2026 | View profile |
| Ronald C. Renaud Jr. CEO & President | ▲ Buy | Option Exercise | 38,094 Shares held | 6/9/2026 | View profile |
Transaction History
| Ronald C. Renaud Jr. | ▲ Buy | Option Exercise | 38,094 | $200K | 6/9/2026 |
| Bain Capital Life Sciences Investors, LLC | ▼ Sell | Other | 4,145,768 | — | 4/20/2026 |
| RTW INVESTMENTS, LP | ▼ Sell | Other | 10,276,820 | — | 4/20/2026 |
| RTW INVESTMENTS, LP | ▲ Buy | Open Market | 500,000 | $8.0M | 4/20/2026 |
| Jiangsu Hengrui Pharmaceuticals Co., Ltd. | ▼ Sell | Other | 9,477,719 | — | 4/20/2026 |
| Jiangsu Hengrui Pharmaceuticals Co., Ltd. | ▼ Sell | Other | 2,034,133 | — | 4/20/2026 |
| BAIN CAPITAL INVESTORS LLC | ▼ Sell | Other | 17,857,143 | — | 4/20/2026 |
| BAIN CAPITAL INVESTORS LLC | ▲ Buy | Open Market | 8,398,438 | $134.4M | 4/20/2026 |
| Adam Koppel | ▼ Sell | Other | 16,875,000 | — | 4/20/2026 |
| Adam Koppel | ▼ Sell | Other | 4,145,768 | — | 4/20/2026 |
| Adam Koppel | ▲ Buy | Open Market | 1,562,500 | $25.0M | 4/20/2026 |
| Bain Capital Life Sciences Investors, LLC | ▼ Sell | Other | 16,875,000 | — | 4/20/2026 |
| Bain Capital Life Sciences Investors, LLC | ▲ Buy | Open Market | 1,562,500 | $25.0M | 4/20/2026 |
| Andrew T. Kaplan | ▼ Sell | Other | 17,857,143 | — | 4/20/2026 |
| Andrew T. Kaplan | ▲ Buy | Open Market | 8,398,438 | $134.4M | 4/20/2026 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 24, 2026
Kailera Therapeutics faces scrutiny on weight loss differentiation
Recent analysis highlights the need for Kailera to clearly differentiate its weight loss drug from existing GLP-1 competitors. The stock is currently trading near its support level, reflecting cautious sentiment as investors await concrete progress on the company's obesity treatment pipeline.
Kailera Therapeutics faces scrutiny on weight loss differentiation. Recent analysis highlights the need for Kailera to clearly differentiate its weight loss drug from existing GLP-1 competitors. The stock is currently trading near its support level, reflecting cautious sentiment as investors await concrete progress on the company's obesity treatment pipeline.